Rekvina Laboratories 2025-26 Annual Report and AGM Notice

The Board of Directors met on 03/09/2026 from 14:00 to 15:10 and approved:

Notice of the 38th Annual General Meeting scheduled for 29/09/2026
Annual Report for Financial Year 2025-26
Appointment of M/s S. Bhattbhatt & Co. (COP No: 10427) as Scrutinizer for e-voting process
Appointment of M/s. Hetanshi Shah & Associates (FRN: 133646W) as Internal Auditor
Noted resignation of Mr. Deepak Khandelwal as Company Secretary and Compliance Officer effective closing hours of 02/09/2026

| Particulars | 2025-26 | 2024-25 |

| Sales Turnover | 126.54 | 0 |

| Total Income | 126.54 | 0 |

| Total Expenditure | 152.01 | 13.71 |

| Net Profit/(Loss) after Tax | (25.47) | (13.71) |

Revenue from operations commenced at ₹126.54 lakhs compared to nil in previous year
Net loss increased to ₹25.47 lakhs from ₹13.71 lakhs in FY 2024-25
Employee benefits expense increased to ₹22.99 lakhs from ₹4.30 lakhs
Borrowings increased to ₹147.27 lakhs from ₹24.69 lakhs
Negative net worth of ₹122.82 lakhs (previous year: ₹33.22 lakhs negative)
EPS: -₹0.42 (previous year: -₹0.23)

Authorized Share Capital increased from ₹3.50 crores to ₹6.00 crores
Board approved acquisition of 100% equity shares of Radiant Parenterals Limited (18,51,100 shares) for ₹4.62 crores
Proposed issuance of 46,27,750 equity shares at ₹10 per share to Radiant shareholders via preferential allotment
Additional preferential issue of 4,60,000 equity shares at ₹10 per share to Mr. Amitkumar Arunkumar Rao and his HUF for ₹46 lakhs cash consideration

Board Composition as on 31/03/2026:

1. Mr. Amit Mukesh Shah - Managing Director

2. Mr. Surbhit Shah - Executive Director & CFO

3. Mr. Prateek Jain - Independent Director (from 06/10/2025)

4. Mr. Jay Patel - Independent Director (from 29/01/2026)

5. Mrs. Ilaben Pathak - Non-Executive Non-Independent Director

Board Changes during FY 2025-26:

Appointments: Mr. Prateek Jain (06/10/2025), Mr. Jay Patel (29/01/2026)
Cessations: Mr. Dhruvalkumar Patel (09/01/2026), Mr. Chetanbhai Patel (29/01/2026)

Board Meetings: 9 meetings held during the year with full attendance by executive directors

Ordinary Business:

1. Adoption of audited financial statements for FY 2025-26

2. Re-appointment of Mrs. Ilaben Pathak (DIN: 01328714) who retires by rotation

Special Business:

3. Appointment of Mr. Prateek Jain (DIN: 08611660) as Independent Director for 5 years from 06/10/2025

4. Appointment of Mr. Jay Chintan Patel (DIN: 10147916) as Independent Director for 5 years from 29/01/2026

Mr. Deepak Khandelwal resigned as Company Secretary and Compliance Officer effective 02/09/2026

Company recognized ₹64.13 lakhs as prior period error for unpaid listing fees and ROC filing fees from earlier years
Adjusted against opening retained earnings as period-wise impact determination was impracticable
Delay in submission of disclosure to stock exchange regarding September 2025 General Meeting proceedings
Non-adherence to Regulation 47 of SEBI LODR Regulations
Certain E-Forms filed with ROC with additional fees

Promoter holding: Surbhit M Shah (15.22%), Amit M Shah (13.73%), Mukesh J Shah (12.34%)
Shares of deceased promoter Mukesh J Shah pending transmission to legal heirs Amit Shah and Surbhit Shah due to lock-in restrictions

No dividend recommended due to losses
No fraud reported by auditors under Section 143
No material orders passed by regulators/courts affecting going concern status
Trading suspension revoked by BSE effective 07/01/2026 after payment of listing fees
Company operates in single segment - pharmaceutical formulations
Register of Members to remain closed from 23/09/2026 to 29/09/2026
Remote e-voting period: 25/09/2026 (9:00 AM) to 28/09/2026 (5:00 PM)

Emphasis of Matter regarding:

1. Pending transmission of deceased promoter's shares due to lock-in restrictions

2. Inability to provide complete MSME creditor bifurcation due to system limitations